RxDoctor Payments Data

Zachary Yoneda

Cardiovascular Disease · Nashville, TNNPI 1740523943

Payments from drug & device makers

What this record shows

This record is dominated by grants: $20,000 of the $27,450 with a category attached, or 72.9%. Medtronic accounts for 84.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $21,144 and has fallen 89.9% since, to $2,145 in 2025. Among cardiovascular disease clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,450in general payments, 2019–2025

Across 75 payments — averaging $365.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$23K
  • Boston Scientific$2K
  • Biotronik Inc.$928
  • Abbott$313
  • Philips North America LLC$311
  • Abiomed$133
  • plus $88 from 2 others
$173,850in research payments, 2019–2025

Across 20 payments — averaging $8692.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$174K

What the payments were for

  • Grants$20,00073%
  • Travel & lodging$2,85710%
  • Food & beverage$4,11315%
  • Education$4802%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,450 in reported general payments places this provider in the 90th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$94,237
Medicare patients
933
Services billed
1,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$88,039
XareltoRivaroxaban12$16,325
Metoprolol Succinate43$838
Flecainide Acetate11$270
Amiodarone Hcl17$222

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →